{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-059424","form_type":"8-K","ticker":"TMDX","cik":"0001756262","company_name":"TransMedics Group, Inc.","filed_at":"2023-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.324625+00:00","generated_at":"2026-06-08T21:16:54.956841+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"TransMedics Q3 revenue $66.4M (+159% YoY); raises FY2023 guidance to $222-230M","bullets":["Revenue $66.4M, up 159% YoY; includes $2.1M from new aviation business and $1.6M non-recurring charter revenue.","Net loss widened to $25.4M from $7.4M, driven by $29.2M non-recurring acquisition costs including $27.2M in-process R&D charge.","Gross margin 61% vs 71% a year ago, impacted by Summit Aviation transition and legacy charter exit costs.","Cash $427.1M as of Sep 30; full-year 2023 revenue guidance raised to $222-230M from prior $180-190M.","Summit Aviation acquisition closed, adding aviation service to organ transplant logistics offering."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-059424","json":"https://secwatch.observer/filing/0000950170-23-059424.json","markdown":"https://secwatch.observer/filing/0000950170-23-059424.md","text":"https://secwatch.observer/filing/0000950170-23-059424.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1756262/000095017023059424/0000950170-23-059424-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1756262/000095017023059424/tmdx-20231106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T21:16:54.956841+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1d1d0a555d1c2f84e7de421951a62d3ef0c10409","claim":"TransMedics Group, Inc. reported quarter ended September 30, 2023 results: revenue $66.4 million. Guidance raised.","evidence_excerpt":"therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2023. Recent Highlights ▪ Net revenue of $66.4 million in the third quarter of 2023, a 159% increase compared to the third quarter of 2022, including $1.6 million non-recurring charter revenue ▪ Closed acquisition of Summit Aviation,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1756262/000095017023059424/0000950170-23-059424-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended September 30, 2023"},{"label":"Revenue","value":"$66.4 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}